PreludeDx

PreludeDx is a leader in personalized breast cancer diagnostics, offering precision tools that empower patients and physicians worldwide to make more informed, shared treatment decisions. The company offers DCISionRT for Ductal Carcinoma In Situ (DCIS) and AidaBreast for early-stage invasive breast cancer, which provide genomic insights into a patient’s unique tumor biology. These personalized, clinically actionable test results help guide surgical and radiation treatment decisions, reducing the risks of over- or undertreatment. The company utilizes multi-omic technology to provide comprehensive prognostic and predictive information at critical treatment decision points to enhance patient care.